Eli Lilly enters 2026 with strong momentum thanks to innovations in its drug pipeline. The company has launched six early-stage clinical programs and 34 discovery programs targeting incretins, amylins and novel targets. In earlier studies, retatrutide produced an average weight loss of nearly 29% in participants, with some losing more than 35%. In comparison, Zepbound allowed up to 21% weight loss over a similar period. Upcoming phase 3 studies — Triumph-1, Triumph-2 and Triumph-3 — are testing retatrutide in more than 5,000 people with obesity, obesity and type 2 diabetes, or obesity and cardiovascular disease. The experimental tablet drug orforglipron successfully met the primary and key secondary objectives in the phase 3 ATTAIN-2 study in adults with obesity or overweight and type 2 diabetes. Orforglipron has helped patients maintain weight loss after stopping injectable drugs like Zepbound.[1][2][4]